Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: An updated meta-analysis of randomized controlled trials
CONCLUSION: In this meta-analysis of RCTs, statins were significantly associated with a lower incidence of anthracycline-induced CTRCD and attenuated changes in the left ventricular end-systolic volume. Thus, our findings suggest that statins should be considered as a cardio-protection strategy for patients with planned anthracycline-based chemotherapy.PMID:38643042 | DOI:10.1016/j.ejim.2024.04.007
Source: European Journal of Internal Medicine - Category: Internal Medicine Authors: Nicole Felix Paula C Nogueira Isadora M Silva Thomaz Alexandre Costa Carlos Alberto Campello Carlos Stecca Renato D Lopes Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Cardiovascular | Chemotherapy | Cholesterol | Databases & Libraries | Heart | Internal Medicine | Science | Statin Therapy